<span item_type="fundamental" item_id="6bb7fbcea1c5c87abc6762c1472bdb16" counter_id="ST/US/SGHT" env="prod"></span><span item_type="announcement" item_id="604405237969388545" env="prod"></span><p>Revenue: As of FY2025 Q4, the actual value is USD 20.3 M, beating the estimate of USD 20.17 M.</p><p></p><h4>Fourth Quarter 2025 Financial Highlights</h4><p>Sight Sciences, Inc.’s total revenue for the fourth quarter of 2025 is expected to be in the range of $20.3 million to $20.4 million, representing an increase of 7% at the estimated midpoint compared to the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. Surgical Glaucoma revenues are expected to be in the range of $19.6 million to $19.7 million, an increase of 5% at the estimated midpoint compared to the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. Dry Eye revenues are expected to be approximately $0.7 million, an increase of approximately 130% compared to the prior year period <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>.</p><h4>Full Year 2025 Financial Highlights</h4><p>Sight Sciences, Inc.’s total revenue for the full year 2025 is expected to be in the range of $77.3 million to $77.4 million, a decrease of 3% at the estimated midpoint compared to the prior year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. Surgical Glaucoma revenues are expected to be in the range of $75.6 million to $75.7 million, remaining flat at the estimated midpoint compared to the prior year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. Dry Eye revenues are expected to be approximately $1.6 million, compared to $4.0 million in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>.</p><h4>Cash and Cash Equivalents</h4><p>As of December 31, 2025, Sight Sciences, Inc.’s cash and cash equivalents were approximately $92 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. This compares to $92.4 million as of September 30, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>.</p><h4>Cash Flow</h4><p>Cash used in the fourth quarter totaled approximately - $0.4 million, reflecting continued operational discipline <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. Cash used during the full year totaled approximately - $28 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>.</p><h4>Outlook / Guidance</h4><p>Sight Sciences, Inc. remains confident in its growth outlook and operational discipline <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. The company expects to achieve cash flow breakeven without requiring additional equity capital <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>. These preliminary, unaudited financial results are subject to the completion of the company’s 2025 audit <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-ex99_1.htm"></span>.</p>

Sight Sciences | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 20.3 M